TD Cowen initiated coverage of Inventiva (IVA) with a Buy rating and $10 price target The firm thinks the company’s oral pan-PPAR agonist lanifibranor will reduce insulin resistance, lower hepatic inflammation, and improve fibrosis in metabolic dysfunction-associated steatohepatitis, with improved tolerability over current PPAR agonists and MASH therapies. TD is positive on the topline data guided for the second half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Optimistic Buy Rating for Inventiva Driven by Lanifibranor’s Promising Phase 3 Prospects and Safety Profile
- Inventiva and Hepalys Initiate Phase 1 Trial for Lanifibranor in Japan
- Inventiva & Japan’s Hepalys start lanifibranor clinical development program
- Buy Rating for Inventiva: Strategic Focus on Lanifibranor and Strong Financial Outlook
- Inventiva Reports 2024 Financials and Strategic Shift to Focus on Lanifibranor